VIDEO: 90 Seconds With… Steven Lydeamore, Anatara Lifesciences
Got 90 seconds? Then listen to Anatara Lifesciences CEO Steven Lydeamore tell us about his company’s gastrointestinal health products and upcoming newsflow.
Anatara Lifesciences (ASX:ANR) is developing and commercialising a range of gastrointestinal health products focused on animal and human health.
The company’s lead product, Detach, is a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour), which affects livestock.
Anatara is also developing Gastrointestinal ReProgramming (GaRP), a microbiome-targeted dietary supplement.
The product is designed to address the primary underlying factors associated with gastrointestinal disorders such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).
So tune in to hear Steven talk about his company’s product range and upcoming newsflow.
Have a good idea for our next 90 Seconds With segment? Email us at [email protected].
SUBSCRIBE
Get the latest breaking news and stocks straight to your inbox.
It's free. Unsubscribe whenever you want.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.